FMC - Oshtemo is a medicare approved dialysis facility center in Kalamazoo, Michigan and it has 24 dialysis stations. It is located in Kalamazoo county at 6739 Seeco Dr, Kalamazoo, MI, 49009. You can reach out to the office of FMC - Oshtemo at (269) 375-5815. This dialysis clinic is managed and/or owned by Fresenius Medical Care. FMC - Oshtemo has the following ownership type - Profit. It was first certified by medicare in August, 1998. The medicare id for this facility is 232560 and it accepts patients under medicare ESRD program.
| Name | FMC - Oshtemo |
|---|---|
| Location | 6739 Seeco Dr, Kalamazoo, Michigan |
| No. of Dialysis Stations | 24 |
| Medicare ID | 232560 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | Yes |
| 6739 Seeco Dr, Kalamazoo, Michigan, 49009 | |
| (269) 375-5815 | |
News Archive
Researchers from the University of Dundee and the Francis Crick Institute have made a significant discovery about a cellular pathway associated with developmental defects and a myriad of diseases ranging from alopecia to colorectal cancer.
Biotechnology company MabCure, Inc. today announced that a confirmatory study demonstrated the company's proprietary monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent accuracy) and with no false positives or cross-reactions with benign ovarian tumors or healthy blood. MabCure's serum diagnostic test is the first to recognize unique tumor markers or cancer fingerprints present only in ovarian cancer, the deadliest of all gynecological cancers.
Nano Bridging Molecules SA, A Swiss med-tech company announced that it has received CE Mark (Conformité Européenne) approval to begin marketing its SurfLink® Dental product. With its bio mimicking properties, SurfLink® Dental has been shown to allow for natural and permanent integration of dental implants for the first time. Bone seems to perceive the SurfLink® Dental product as ‘body-like' and integrates the implant with a natural healing process, resulting in a quicker healing and a more stable integration, than without this product.
ERT, a leading provider of centralized services to the biopharmaceutical, medical device and related industries, today announced its new ERT Knowledge Series of educational papers, written by ERT experts. Each paper discusses issues relevant to patient safety in clinical trials today and further establishes ERT as an experienced and reliable partner in products and services for the clinical trials industry.
› Verified 1 days ago
| NPI Number | 1811939622 |
| Organization Name | Rcg Oshtemo |
| Doing Business As | Renal Care Group Southwest Michigan, Llc |
| Address | 6739 Seeco Dr Kalamazoo, Michigan, 49009 |
| Phone Number | (269) 375-5815 |
News Archive
Researchers from the University of Dundee and the Francis Crick Institute have made a significant discovery about a cellular pathway associated with developmental defects and a myriad of diseases ranging from alopecia to colorectal cancer.
Biotechnology company MabCure, Inc. today announced that a confirmatory study demonstrated the company's proprietary monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent accuracy) and with no false positives or cross-reactions with benign ovarian tumors or healthy blood. MabCure's serum diagnostic test is the first to recognize unique tumor markers or cancer fingerprints present only in ovarian cancer, the deadliest of all gynecological cancers.
Nano Bridging Molecules SA, A Swiss med-tech company announced that it has received CE Mark (Conformité Européenne) approval to begin marketing its SurfLink® Dental product. With its bio mimicking properties, SurfLink® Dental has been shown to allow for natural and permanent integration of dental implants for the first time. Bone seems to perceive the SurfLink® Dental product as ‘body-like' and integrates the implant with a natural healing process, resulting in a quicker healing and a more stable integration, than without this product.
ERT, a leading provider of centralized services to the biopharmaceutical, medical device and related industries, today announced its new ERT Knowledge Series of educational papers, written by ERT experts. Each paper discusses issues relevant to patient safety in clinical trials today and further establishes ERT as an experienced and reliable partner in products and services for the clinical trials industry.
› Verified 1 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 70% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 17% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 13% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 57% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 28% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 15% | 14% |
News Archive
Researchers from the University of Dundee and the Francis Crick Institute have made a significant discovery about a cellular pathway associated with developmental defects and a myriad of diseases ranging from alopecia to colorectal cancer.
Biotechnology company MabCure, Inc. today announced that a confirmatory study demonstrated the company's proprietary monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent accuracy) and with no false positives or cross-reactions with benign ovarian tumors or healthy blood. MabCure's serum diagnostic test is the first to recognize unique tumor markers or cancer fingerprints present only in ovarian cancer, the deadliest of all gynecological cancers.
Nano Bridging Molecules SA, A Swiss med-tech company announced that it has received CE Mark (Conformité Européenne) approval to begin marketing its SurfLink® Dental product. With its bio mimicking properties, SurfLink® Dental has been shown to allow for natural and permanent integration of dental implants for the first time. Bone seems to perceive the SurfLink® Dental product as ‘body-like' and integrates the implant with a natural healing process, resulting in a quicker healing and a more stable integration, than without this product.
ERT, a leading provider of centralized services to the biopharmaceutical, medical device and related industries, today announced its new ERT Knowledge Series of educational papers, written by ERT experts. Each paper discusses issues relevant to patient safety in clinical trials today and further establishes ERT as an experienced and reliable partner in products and services for the clinical trials industry.
› Verified 1 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 75% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 16% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 9% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 78% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 16% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 6% | 12% |
News Archive
Researchers from the University of Dundee and the Francis Crick Institute have made a significant discovery about a cellular pathway associated with developmental defects and a myriad of diseases ranging from alopecia to colorectal cancer.
Biotechnology company MabCure, Inc. today announced that a confirmatory study demonstrated the company's proprietary monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent accuracy) and with no false positives or cross-reactions with benign ovarian tumors or healthy blood. MabCure's serum diagnostic test is the first to recognize unique tumor markers or cancer fingerprints present only in ovarian cancer, the deadliest of all gynecological cancers.
Nano Bridging Molecules SA, A Swiss med-tech company announced that it has received CE Mark (Conformité Européenne) approval to begin marketing its SurfLink® Dental product. With its bio mimicking properties, SurfLink® Dental has been shown to allow for natural and permanent integration of dental implants for the first time. Bone seems to perceive the SurfLink® Dental product as ‘body-like' and integrates the implant with a natural healing process, resulting in a quicker healing and a more stable integration, than without this product.
ERT, a leading provider of centralized services to the biopharmaceutical, medical device and related industries, today announced its new ERT Knowledge Series of educational papers, written by ERT experts. Each paper discusses issues relevant to patient safety in clinical trials today and further establishes ERT as an experienced and reliable partner in products and services for the clinical trials industry.
› Verified 1 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 80% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 20% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 84% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 14% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 2% | 12% |
News Archive
Researchers from the University of Dundee and the Francis Crick Institute have made a significant discovery about a cellular pathway associated with developmental defects and a myriad of diseases ranging from alopecia to colorectal cancer.
Biotechnology company MabCure, Inc. today announced that a confirmatory study demonstrated the company's proprietary monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent accuracy) and with no false positives or cross-reactions with benign ovarian tumors or healthy blood. MabCure's serum diagnostic test is the first to recognize unique tumor markers or cancer fingerprints present only in ovarian cancer, the deadliest of all gynecological cancers.
Nano Bridging Molecules SA, A Swiss med-tech company announced that it has received CE Mark (Conformité Européenne) approval to begin marketing its SurfLink® Dental product. With its bio mimicking properties, SurfLink® Dental has been shown to allow for natural and permanent integration of dental implants for the first time. Bone seems to perceive the SurfLink® Dental product as ‘body-like' and integrates the implant with a natural healing process, resulting in a quicker healing and a more stable integration, than without this product.
ERT, a leading provider of centralized services to the biopharmaceutical, medical device and related industries, today announced its new ERT Knowledge Series of educational papers, written by ERT experts. Each paper discusses issues relevant to patient safety in clinical trials today and further establishes ERT as an experienced and reliable partner in products and services for the clinical trials industry.
› Verified 1 days ago
| Dialysis patients with Hemoglobin data | 52 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 15 |
| Medicare patients who had average hemoglobin (hgb) greater than 12 g/dL | 2 |
News Archive
Researchers from the University of Dundee and the Francis Crick Institute have made a significant discovery about a cellular pathway associated with developmental defects and a myriad of diseases ranging from alopecia to colorectal cancer.
Biotechnology company MabCure, Inc. today announced that a confirmatory study demonstrated the company's proprietary monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent accuracy) and with no false positives or cross-reactions with benign ovarian tumors or healthy blood. MabCure's serum diagnostic test is the first to recognize unique tumor markers or cancer fingerprints present only in ovarian cancer, the deadliest of all gynecological cancers.
Nano Bridging Molecules SA, A Swiss med-tech company announced that it has received CE Mark (Conformité Européenne) approval to begin marketing its SurfLink® Dental product. With its bio mimicking properties, SurfLink® Dental has been shown to allow for natural and permanent integration of dental implants for the first time. Bone seems to perceive the SurfLink® Dental product as ‘body-like' and integrates the implant with a natural healing process, resulting in a quicker healing and a more stable integration, than without this product.
ERT, a leading provider of centralized services to the biopharmaceutical, medical device and related industries, today announced its new ERT Knowledge Series of educational papers, written by ERT experts. Each paper discusses issues relevant to patient safety in clinical trials today and further establishes ERT as an experienced and reliable partner in products and services for the clinical trials industry.
› Verified 1 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 94 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 785 |
| Percentage of adult patients getting regular hemodialysis at the center | 98 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Researchers from the University of Dundee and the Francis Crick Institute have made a significant discovery about a cellular pathway associated with developmental defects and a myriad of diseases ranging from alopecia to colorectal cancer.
Biotechnology company MabCure, Inc. today announced that a confirmatory study demonstrated the company's proprietary monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent accuracy) and with no false positives or cross-reactions with benign ovarian tumors or healthy blood. MabCure's serum diagnostic test is the first to recognize unique tumor markers or cancer fingerprints present only in ovarian cancer, the deadliest of all gynecological cancers.
Nano Bridging Molecules SA, A Swiss med-tech company announced that it has received CE Mark (Conformité Européenne) approval to begin marketing its SurfLink® Dental product. With its bio mimicking properties, SurfLink® Dental has been shown to allow for natural and permanent integration of dental implants for the first time. Bone seems to perceive the SurfLink® Dental product as ‘body-like' and integrates the implant with a natural healing process, resulting in a quicker healing and a more stable integration, than without this product.
ERT, a leading provider of centralized services to the biopharmaceutical, medical device and related industries, today announced its new ERT Knowledge Series of educational papers, written by ERT experts. Each paper discusses issues relevant to patient safety in clinical trials today and further establishes ERT as an experienced and reliable partner in products and services for the clinical trials industry.
› Verified 1 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at FMC - Oshtemo with elevated calcium levels.
| Patients with hypercalcemia | 112 |
| Hypercalcemia patient months | 924 |
| Patients with Serumphosphor | 123 |
| Patients with Serumphosphor less than 3.5 mg/dL | 8 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 27 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 33 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 24 |
| Patients with Serumphosphor greater than 7 mg/dL | 8 |
News Archive
Researchers from the University of Dundee and the Francis Crick Institute have made a significant discovery about a cellular pathway associated with developmental defects and a myriad of diseases ranging from alopecia to colorectal cancer.
Biotechnology company MabCure, Inc. today announced that a confirmatory study demonstrated the company's proprietary monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent accuracy) and with no false positives or cross-reactions with benign ovarian tumors or healthy blood. MabCure's serum diagnostic test is the first to recognize unique tumor markers or cancer fingerprints present only in ovarian cancer, the deadliest of all gynecological cancers.
Nano Bridging Molecules SA, A Swiss med-tech company announced that it has received CE Mark (Conformité Européenne) approval to begin marketing its SurfLink® Dental product. With its bio mimicking properties, SurfLink® Dental has been shown to allow for natural and permanent integration of dental implants for the first time. Bone seems to perceive the SurfLink® Dental product as ‘body-like' and integrates the implant with a natural healing process, resulting in a quicker healing and a more stable integration, than without this product.
ERT, a leading provider of centralized services to the biopharmaceutical, medical device and related industries, today announced its new ERT Knowledge Series of educational papers, written by ERT experts. Each paper discusses issues relevant to patient safety in clinical trials today and further establishes ERT as an experienced and reliable partner in products and services for the clinical trials industry.
› Verified 1 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 101 |
| Patient months included in arterial venous fistula and catheter summaries | 755 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 65 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 5 |
News Archive
Researchers from the University of Dundee and the Francis Crick Institute have made a significant discovery about a cellular pathway associated with developmental defects and a myriad of diseases ranging from alopecia to colorectal cancer.
Biotechnology company MabCure, Inc. today announced that a confirmatory study demonstrated the company's proprietary monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent accuracy) and with no false positives or cross-reactions with benign ovarian tumors or healthy blood. MabCure's serum diagnostic test is the first to recognize unique tumor markers or cancer fingerprints present only in ovarian cancer, the deadliest of all gynecological cancers.
Nano Bridging Molecules SA, A Swiss med-tech company announced that it has received CE Mark (Conformité Européenne) approval to begin marketing its SurfLink® Dental product. With its bio mimicking properties, SurfLink® Dental has been shown to allow for natural and permanent integration of dental implants for the first time. Bone seems to perceive the SurfLink® Dental product as ‘body-like' and integrates the implant with a natural healing process, resulting in a quicker healing and a more stable integration, than without this product.
ERT, a leading provider of centralized services to the biopharmaceutical, medical device and related industries, today announced its new ERT Knowledge Series of educational papers, written by ERT experts. Each paper discusses issues relevant to patient safety in clinical trials today and further establishes ERT as an experienced and reliable partner in products and services for the clinical trials industry.
› Verified 1 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 101 |
| Hospitalization Rate in facility | 169 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 278.8 |
| Hospitalization Rate: Lower Confidence Limit | 105.3 |
News Archive
Researchers from the University of Dundee and the Francis Crick Institute have made a significant discovery about a cellular pathway associated with developmental defects and a myriad of diseases ranging from alopecia to colorectal cancer.
Biotechnology company MabCure, Inc. today announced that a confirmatory study demonstrated the company's proprietary monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent accuracy) and with no false positives or cross-reactions with benign ovarian tumors or healthy blood. MabCure's serum diagnostic test is the first to recognize unique tumor markers or cancer fingerprints present only in ovarian cancer, the deadliest of all gynecological cancers.
Nano Bridging Molecules SA, A Swiss med-tech company announced that it has received CE Mark (Conformité Européenne) approval to begin marketing its SurfLink® Dental product. With its bio mimicking properties, SurfLink® Dental has been shown to allow for natural and permanent integration of dental implants for the first time. Bone seems to perceive the SurfLink® Dental product as ‘body-like' and integrates the implant with a natural healing process, resulting in a quicker healing and a more stable integration, than without this product.
ERT, a leading provider of centralized services to the biopharmaceutical, medical device and related industries, today announced its new ERT Knowledge Series of educational papers, written by ERT experts. Each paper discusses issues relevant to patient safety in clinical trials today and further establishes ERT as an experienced and reliable partner in products and services for the clinical trials industry.
› Verified 1 days ago
The rate of readmission show you whether patients who were being treated regularly at FMC - Oshtemo were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 15.1 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 23.8 |
| Readmission Rate: Lower Confidence Limit | 8.7 |
News Archive
Researchers from the University of Dundee and the Francis Crick Institute have made a significant discovery about a cellular pathway associated with developmental defects and a myriad of diseases ranging from alopecia to colorectal cancer.
Biotechnology company MabCure, Inc. today announced that a confirmatory study demonstrated the company's proprietary monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent accuracy) and with no false positives or cross-reactions with benign ovarian tumors or healthy blood. MabCure's serum diagnostic test is the first to recognize unique tumor markers or cancer fingerprints present only in ovarian cancer, the deadliest of all gynecological cancers.
Nano Bridging Molecules SA, A Swiss med-tech company announced that it has received CE Mark (Conformité Européenne) approval to begin marketing its SurfLink® Dental product. With its bio mimicking properties, SurfLink® Dental has been shown to allow for natural and permanent integration of dental implants for the first time. Bone seems to perceive the SurfLink® Dental product as ‘body-like' and integrates the implant with a natural healing process, resulting in a quicker healing and a more stable integration, than without this product.
ERT, a leading provider of centralized services to the biopharmaceutical, medical device and related industries, today announced its new ERT Knowledge Series of educational papers, written by ERT experts. Each paper discusses issues relevant to patient safety in clinical trials today and further establishes ERT as an experienced and reliable partner in products and services for the clinical trials industry.
› Verified 1 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at FMC - Oshtemo get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .77 (As Expected) |
| SIR: Upper Confidence Limit | 1.86 |
| SIR: Lower Confidence Limit | .25 |
News Archive
Researchers from the University of Dundee and the Francis Crick Institute have made a significant discovery about a cellular pathway associated with developmental defects and a myriad of diseases ranging from alopecia to colorectal cancer.
Biotechnology company MabCure, Inc. today announced that a confirmatory study demonstrated the company's proprietary monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent accuracy) and with no false positives or cross-reactions with benign ovarian tumors or healthy blood. MabCure's serum diagnostic test is the first to recognize unique tumor markers or cancer fingerprints present only in ovarian cancer, the deadliest of all gynecological cancers.
Nano Bridging Molecules SA, A Swiss med-tech company announced that it has received CE Mark (Conformité Européenne) approval to begin marketing its SurfLink® Dental product. With its bio mimicking properties, SurfLink® Dental has been shown to allow for natural and permanent integration of dental implants for the first time. Bone seems to perceive the SurfLink® Dental product as ‘body-like' and integrates the implant with a natural healing process, resulting in a quicker healing and a more stable integration, than without this product.
ERT, a leading provider of centralized services to the biopharmaceutical, medical device and related industries, today announced its new ERT Knowledge Series of educational papers, written by ERT experts. Each paper discusses issues relevant to patient safety in clinical trials today and further establishes ERT as an experienced and reliable partner in products and services for the clinical trials industry.
› Verified 1 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether FMC - Oshtemo's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 77 |
| Transfusion Rate in facility | 35 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 87.1 |
| Transfusion Rate: Lower Confidence Limit | 15.7 |
News Archive
Researchers from the University of Dundee and the Francis Crick Institute have made a significant discovery about a cellular pathway associated with developmental defects and a myriad of diseases ranging from alopecia to colorectal cancer.
Biotechnology company MabCure, Inc. today announced that a confirmatory study demonstrated the company's proprietary monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent accuracy) and with no false positives or cross-reactions with benign ovarian tumors or healthy blood. MabCure's serum diagnostic test is the first to recognize unique tumor markers or cancer fingerprints present only in ovarian cancer, the deadliest of all gynecological cancers.
Nano Bridging Molecules SA, A Swiss med-tech company announced that it has received CE Mark (Conformité Européenne) approval to begin marketing its SurfLink® Dental product. With its bio mimicking properties, SurfLink® Dental has been shown to allow for natural and permanent integration of dental implants for the first time. Bone seems to perceive the SurfLink® Dental product as ‘body-like' and integrates the implant with a natural healing process, resulting in a quicker healing and a more stable integration, than without this product.
ERT, a leading provider of centralized services to the biopharmaceutical, medical device and related industries, today announced its new ERT Knowledge Series of educational papers, written by ERT experts. Each paper discusses issues relevant to patient safety in clinical trials today and further establishes ERT as an experienced and reliable partner in products and services for the clinical trials industry.
› Verified 1 days ago
The rate of mortality show you whether patients who were being treated regularly at FMC - Oshtemo lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 485 |
| Mortality Rate in facility | 15.1 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 19.4 |
| Mortality Rate: Lower Confidence Limit | 11.6 |
News Archive
Researchers from the University of Dundee and the Francis Crick Institute have made a significant discovery about a cellular pathway associated with developmental defects and a myriad of diseases ranging from alopecia to colorectal cancer.
Biotechnology company MabCure, Inc. today announced that a confirmatory study demonstrated the company's proprietary monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent accuracy) and with no false positives or cross-reactions with benign ovarian tumors or healthy blood. MabCure's serum diagnostic test is the first to recognize unique tumor markers or cancer fingerprints present only in ovarian cancer, the deadliest of all gynecological cancers.
Nano Bridging Molecules SA, A Swiss med-tech company announced that it has received CE Mark (Conformité Européenne) approval to begin marketing its SurfLink® Dental product. With its bio mimicking properties, SurfLink® Dental has been shown to allow for natural and permanent integration of dental implants for the first time. Bone seems to perceive the SurfLink® Dental product as ‘body-like' and integrates the implant with a natural healing process, resulting in a quicker healing and a more stable integration, than without this product.
ERT, a leading provider of centralized services to the biopharmaceutical, medical device and related industries, today announced its new ERT Knowledge Series of educational papers, written by ERT experts. Each paper discusses issues relevant to patient safety in clinical trials today and further establishes ERT as an experienced and reliable partner in products and services for the clinical trials industry.
› Verified 1 days ago
FMC - Kalamazoo Pd Unit Location: 527 E Michigan Ave, Kalamazoo, Michigan, 49007 Phone: (269) 384-6191 |
Davita - Kalamazoo Central Location: 535 S Burdick St Ste 110, Kalamazoo, Michigan, 49007 Phone: (269) 343-0251 |
News Archive
Researchers from the University of Dundee and the Francis Crick Institute have made a significant discovery about a cellular pathway associated with developmental defects and a myriad of diseases ranging from alopecia to colorectal cancer.
Biotechnology company MabCure, Inc. today announced that a confirmatory study demonstrated the company's proprietary monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent accuracy) and with no false positives or cross-reactions with benign ovarian tumors or healthy blood. MabCure's serum diagnostic test is the first to recognize unique tumor markers or cancer fingerprints present only in ovarian cancer, the deadliest of all gynecological cancers.
Nano Bridging Molecules SA, A Swiss med-tech company announced that it has received CE Mark (Conformité Européenne) approval to begin marketing its SurfLink® Dental product. With its bio mimicking properties, SurfLink® Dental has been shown to allow for natural and permanent integration of dental implants for the first time. Bone seems to perceive the SurfLink® Dental product as ‘body-like' and integrates the implant with a natural healing process, resulting in a quicker healing and a more stable integration, than without this product.
ERT, a leading provider of centralized services to the biopharmaceutical, medical device and related industries, today announced its new ERT Knowledge Series of educational papers, written by ERT experts. Each paper discusses issues relevant to patient safety in clinical trials today and further establishes ERT as an experienced and reliable partner in products and services for the clinical trials industry.
› Verified 1 days ago